Area of Focus: Oncology

We are developing novel small molecule inhibitors to a metabolic target, ACSS2, as a treatment for solid tumors. We have shown our small molecule drug to be safe and tolerable in a phase 1 clinical study, and slowed disease progression for one-third. This novel approach centers around modifying epigenetic effectors that cause chemo resistance by upregulating DNA damage repair genes. We are planning a phase 1/2 study now for metastatic colorectal cancer by combining our drug with chemo.